Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

ABLYNX TO PRESENT AT THE 32nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE AND TO PROVIDE AN UPDATE ON ITS TTP PROGRAMME



ABLYNX TO PRESENT AT THE 32nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE AND TO
PROVIDE AN UPDATE ON ITS TTP PROGRAMME

GHENT, Belgium, Jan. 13, 2014  (GLOBE NEWSWIRE) -- Ablynx [Euronext  Brussels: 
ABLX] today announced  that it will  present at the  32^nd Annual J.P.  Morgan 
Healthcare Conference on Thursday 16 January  2014, at 2:00 p.m. Pacific  Time 
(5:00 p.m. Eastern Time).

Dr Edwin Moses, CEO  of Ablynx, will give  a corporate presentation that  will 
include an update on the  Company's anti-vWF Nanobody, caplacizumab, to  treat 
acquired thrombotic  thrombocytopenic purpura  (TTP), a  rare blood  disorder. 
Some improvement  in recruitment  has been  seen since  amending the  clinical 
protocol  in  September  2013,  nevertheless,  Ablynx  has  decided  to   stop 
recruitment of  the  trial now  to  allow earlier  analysis  of the  data  for 
potential proof-of-concept. Phase II  data are now  expected during the  first 
half of  2014  and  if  the  results are  promising,  a  Phase  III  study  is 
anticipated to commence in 2015.

The slides may be  accessed via the  Company's website, www.ablynx.com,  under 
the 'News and Events>upcoming events' section.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has approximately  30  programmes in  the  pipeline and  seven  Nanobodies  in 
clinical  development.  Ablynx  has   on-going  research  collaborations   and 
significant partnerships with major pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis.  The 
Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:   +44 207 920 2345
e:  ablynx@consilium-comms.com

pdf version of the press release http://hugin.info/137912/R/1754015/591769.pdf

HUG#1754015
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement